Australia's most trusted
source of pharma news
Saturday, 22 February 2025
Posted 25 July 2024 AM
The current top-valued investigational drug candidates could rake in combined global sales of almost US$65 billion in 2030, if successfully launched.
An updated list in Evaluate's latest report ranks the leading 10 R&D programs by net present value (NPV) with Novo Nordisk's CagriSema and Eli Lilly's orforglipron, still easily holding onto first and second positions, respectively.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.